The Evaluation of Antiproliferative Effect of Imatinib derivatives Against Breast and Colon Cell-Lines

Main Article Content

Ali N. Hussein
Omar f. Abdul- Rasheed
Monther F. Mahdi
Ayad M R Raauf

Abstract

Background: Cancer is considered as one of the major leading causes of death. Tyrosine kinase inhibitors are recognized for their potential antiproliferative effects.
Materials and methods: In the previous study, the authors designed, synthesized, and characterized two imatinib derivatives. These derivatives were biologically evaluated with the utilization of MCF-7, HCT116, and MDCK cell lines. Results: In respect to the imatinib standard, compound 2b has superior activity against HCT116 cell line (IC50; 15.88 μg/mL against 18.52 μg/mL for imatinib) and an improved cytotoxic activity on MDCK cell line (IC50; 0.654 mg/mL against 0.272 mg/mL for imatinib).
Conclusion: The two synthesized compounds showed biological activity against cancerous cell lines and improved cytotoxic activity against normal non-cancerous cell line with respect to the imatinib standard.

Article Details

How to Cite
1.
Hussein A, Abdul- Rasheed O, Mahdi M, Raauf A. The Evaluation of Antiproliferative Effect of Imatinib derivatives Against Breast and Colon Cell-Lines. IJPQA [Internet]. 25Jan.2013 [cited 2Jul.2020];11(01):74-2. Available from: https://www.ijpqa.com/index.php/IJPQA/article/view/976
Section
Research Article